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Introduction: The prognostic value of histopathologic classifications 
of thymoma is debated. Problematic reproducibility might cause this 
controversy. We studied the prognostic significance of three histo-
pathologic classifications of thymomas after three thoracic patholo-
gists agreed upon thymoma subtype and invasion. We also compared 
the outcome to established prognostic parameters.
Methods: Patients, surgically treated for thymic epithelial neoplasm 
at Mayo Clinic (1942–2008), were staged according to the modified 
Masaoka staging and the recently proposed staging by Moran. Three 
thoracic pathologists independently classified all cases according to 
the World Health Organization, Bernatz, and proposed Suster and 
Moran classification. Only thymoma that all three pathologists diag-
nosed as the same histopathologic subtype and extent of invasion 
were included in outcome analysis.
Results: In 214 (proposed Suster and Moran classification), 145 
(World Health Organization classification), and 120 cases (Bernatz 
classification), reviewers agreed upon subtype of thymoma and 
invasion and follow-up was available. Median follow-up time was 
7.5–7.7 years (range between classifications). All histopathologic 
classifications were associated with overall survival (OS) and dis-
ease-free survival (p ≤ 0.0001 to p = 0.048); only Bernatz classifica-
tion was independent of modified Masaoka staging associated with 
OS (p = 0.04). Modified Masaoka stage predicted outcome inde-
pendent of all histopathologic classifications and resection status 
and strongly correlated with the proposed Moran stage (correlation 
coefficient, 0.95). Thymoma size and age were prognostic param-
eters for OS independent of any histopathologic classification.
Conclusions: Histopathologic classifications of thymomas are asso-
ciated with prognosis but are in general not independent predictors 
of outcome. Modified Masaoka stage and proposed Moran staging 
are independent prognostic parameters for thymoma and superior to 
histopathologic classifications.
Key Words: Modified Masaoka staging, Moran staging, WHO 
classification, Bernatz classification, Proposed Suster and Moran 
classification.
(J Thorac Oncol. 2015;10: 691–700)
Modified Masaoka staging and complete resection con-sistently have been shown to predict prognosis in thy-
moma.1–5 Recently, Moran et al.6 also proposed a staging 
system for thymoma and showed correlation with outcome. 
Although currently the World Health Organization (WHO) 
classification is used for the morphologic classification of thy-
momas, several histological classifications have been proposed 
and used in the past; however, their prognostic significance 
and ability to guide further treatment have been controversial.
Evidence suggests that histopathologic reproducibility 
of thymomas might be problematic with only moderate to 
substantial interobserver agreement for the WHO classifica-
tion with reported κ values of 0.45–0.657–9; only one study 
achieved good agreement using a weighted κ (κ = 0.87).10 
Moreover, in an analysis of 456 patients, we recently demon-
strated that the interobserver variability in the classification of 
the histologic type using the current WHO classification,11 the 
classification by Bernatz12 and the previously proposed clas-
sification by Suster and Moran (S&M)13 affects the prognostic 
value of the histologic classification.9 In addition, Zucali et 
al.7 showed that problematic reproducibility of the morpho-
logic classification of thymomas has some effect on patient 
management. Furthermore, although thymomas are consid-
ered malignant, patients usually have a favorable prognosis. 
Therefore, long-term follow-up is essential for outcome stud-
ies. Moreover, studies have been limited by a relative low 
incidence of thymomas. These difficulties might explain, at 
least in part, the variable prognostic results for histologic clas-
sifications. To exclude the effect of interobserver variability, 
in this study, we focused only on cases in which three tho-
racic pathologists independently agreed upon histologic type 
and invasion. Thus, this represents an idealized cohort which 
is perhaps not directly applicable to routine clinical care, but 
provides a mean to assess the innate predictive capacity of sev-
eral histologic classifications and staging systems. We studied 
the prognostic value of clinical features and histopathologic 
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classifications including the current WHO classification, the 
classification by Bernatz, and the proposed S&M classifica-
tion in thymomas that were independently classified as the 
same subtype by three thoracic pathologists. We also com-
pared the prognostic value of clinicopathologic staging sys-
tems such as modified Masaoka stage and the staging system 
that was recently proposed by Moran and clinical parameter to 
identify important prognostic features of thymomas.
PATIENTS AND METHODS
Patients
All cases from patients who underwent surgery for 
thymic epithelial neoplasm at Mayo Clinic between 1942 
and 2008 were collected (these patients are part of a previ-
ously reported patient population).9 In our database, we only 
included patients until 2008 to allow for a reasonable follow-
up time. Medical records were studied including the surgical 
reports. Tumor size was measured at time of gross examina-
tion of the specimen. Tumor size was used in complete and 
incomplete resection specimens but not biopsies. Based on 
microscopic assessment of invasion and extent of tumor as 
described in the surgical report, patients were staged accord-
ing to the modified Masaoka staging and the recently proposed 
staging by Moran et al. as previously summarized.9
The Institutional Review Board of Mayo Clinic 
Rochester approved the study (IRB# 08-003478).
Histopathologic Classification
All cases were reviewed by three thoracic pathologists 
(ACR, ESY, MCA), who were blinded to outcome and inde-
pendently classified thymomas according to the current WHO 
classification, the Bernatz classification and the proposed 
S&M classification as previously summarized.9
If more than one subtype was present, the predominant 
subtype was used for analysis. Any case that was thought to 
be thymic carcinoma by one or more reviewers was excluded 
from the study.
Invasion was categorized according to the current WHO 
classification as recently summarized.9
Only thymomas that were diagnosed as the same histo-
logic subtype and same extent of invasion by all three review-
ers were included in outcome analysis.
Statistical Analysis
The Pearson correlation coefficient was calculated to 
measure the association between modified Masaoka and pro-
posed Moran staging (considering them continuously).
Two types of survival analyses were conducted: Overall 
survival (OS) and disease-free survival (DFS). Survival curves 
were estimated using the Kaplan–Meier method and were com-
pared across categorical predictors using log-rank tests. The 
5-year survival estimates were calculated using the Kaplan–Meier 
method. Univariate associations among patient characteristics, 
histopathologic classifications, and staging with outcome (OS 
and DFS) were assessed with Cox proportional hazards regres-
sion models. Multivariable Cox proportional hazards regression 
was used to estimate the overall effects of each staging type and 
histopathologic classification, adjusted for additional character-
istics (age, weight loss at presentation, thymoma size, resection 
status, and modified Masaoka stage). Hazard ratios and 95% 
confidence intervals (CI) were reported. Harrell’s c-index was 
used as a measure of the predictive accuracy for each model.14 
The c-index can range from 0 to 1, and larger values indicate 
better predictability from the model; a value of 0.5 indicates that 
the model does no better than chance alone.
All analyses were performed using SAS version 9 
(Cary, NC). All p values reported are unadjusted for multiple 
testing so the reader may interpret at his or her own discretion. 
Overall p values less than 0.05 were considered statistically 
significant. Furthermore, pairwise comparisons (i.e., compar-
ing between WHO subtypes) were regarded as statistically 
significant if the p value was less than 0.05 divided by the 
number of possible comparisons (Bonferroni).
RESULTS
All three reviewers agreed upon a diagnosis of thymoma 
in 413 cases (of 456). Figure 1 presents numbers of reviewed 
thymomas, histopathologic agreement, available follow-up, 
and statistically analyzed cases. A median of three slides per 
tumor (range, 1–32) was available for review, correspondent to 
a median of 0.5 slides per cm tumor. The clinical characteristics 
of the patients are summarized in Table 1. Follow-up was avail-
able in 376 patients. The overall 5-year DFS estimate was 91.7% 
(95% CI: 88.6%–94.9%); the OS estimate was 75.8% (95% CI: 
71.2%–80.4%). The median survival estimate could not be cal-
culated as the median was never reached (too few events).
Table 2 summarizes the outcome of patients with thy-
moma by morphologic classification. The median follow-up 
time and 5-year DFS and OS estimates are similar between the 
histopathologic classifications.
WHO, Bernatz, and Proposed Suster & Moran 
Classifications Are of Prognostic Significance 
for Thymoma but Only Bernatz Classification 
Is Independent of Modified Masaoka Stage
In univariate analysis, all three studied histopatho-
logic classifications are significantly associated with OS and 
DFS (Table 3). Kaplan–Meier curves for OS are illustrated 
FIGURE 1.  Numbers of reviewed thymomas, morphologic 
agreement, available follow-up, and statistically analyzed cases.
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in Figure 2. For WHO, type B1 thymomas have the best 
OS followed by types AB, A, B2, and B3. In comparing the 
subtypes in a pairwise fashion (using a Bonferroni-adjusted 
significance level of 0.005, 10 comparisons), type B3 thymo-
mas have significantly worse survival as compared with AB 
(p = 0.0007) and B1 (p = 0.0007) thymomas. The OS of types 
A and AB thymomas are not significantly different from type 
B1 thymomas. Type AB thymomas have a better DFS than 
type A thymomas followed by B1, B2, and B3. After compar-
ing the subtypes in a pairwise fashion, B3 thymomas have sig-
nificantly worse DFS as compared with type AB (p = 0.003).
For the Bernatz classification, lymphocyte predominant 
thymomas have the best OS followed by mixed epithelial cell & 
lymphocyte, spindle cell predominant and epithelial predominant 
thymomas. In comparing the subtypes in a pairwise fashion (using 
a Bonferroni-adjusted significance level of 0.008, six compari-
sons), epithelial predominant type thymomas have a significantly 
worse OS than lymphocyte predominant thymomas (p = 0.0004). 
Spindle cell thymomas have the best DFS followed by lympho-
cyte predominant, epithelial cell & lymphocyte thymomas, and 
epithelial predominant thymomas; however, none of the pairwise 
comparisons for DFS reached the 0.008 level of significance.
In multivariate analysis, all three histopathologic clas-
sifications continue to be significant for OS when adjusted 
for age and sex; WHO and proposed S&M classifications 
are significant for OS when adjusted for thymoma size but 
only Bernatz classification is significant for OS if adjusted for 
modified Masaoka stage (Table 4).
WHO and proposed S&M classifications continue to be 
significant for DFS when adjusted for thymoma size; WHO 
classification is also significant for DFS when adjusted for 
age and sex (Table 4). However, when adjusted for modified 
Masaoka stage, WHO and proposed S&M classification are 
no longer significant for DFS. Because of the small number of 
recurrences and/or metastases, these results may be unstable 
and should be regarded as suggestive only. For Bernatz, there 
are too few cases for multivariate analysis.
Modified Masaoka Stage and Proposed 
Moran Stage Are Independent 
Prognostic Parameters for Thymoma
Univariate analysis for all three histopathologic classi-
fications studied (WHO, proposed S&M, and Bernatz clas-
sification) shows that modified Masaoka stage and proposed 
Moran stage are significant for OS and DFS (Table 3). For 
all histopathologic classifications, modified Masaoka stage I 
thymoma have the best OS and stage IV the worst.
The OS was compared between the Masaoka stages in 
a pairwise fashion, using a Bonferroni-adjusted significance 
level of 0.008 (six comparisons). Most comparisons were sig-
nificant (nonsignificant comparison p values shown in bold 
italic). For the WHO, Bernatz and proposed S&M classifica-
tions, modified Masaoka stage I generally had a better OS than 
stage II (p = 0.002, p = 0.03, p = 0.005, respectively), stage III 
(p = 0.006, p = 0.048, p = 0.001, respectively), or stage IV 
(p < 0.0001, p = 0.0002, p < 0.0001, respectively); stage II 
patients generally had a better OS than stage IV patients 
(p = 0.005, p = 0.03, p = 0.005, respectively) and stage III had a 
better OS than stage IV (p = 0.0004, p = 0.007, p = 0.003, 
respectively).
Similarly, for the proposed Moran classification (using a 
Bonferroni-adjusted significance level of 0.005, 10 compari-
sons), stage 0 had the best and stage IIIa/b the worst prognosis, 
with stage IIc patients having the second to worst prognosis. 
For all three histopathologic classifications, patients with stage 
IIa/b or IIc have similar OS as compared with patients with 
stage I. For the WHO, Bernatz, and proposed S&M classifi-
cations, patients with stage 0 thymoma had a better OS than 
stage I (p = 0.002, p = 0.002, p = 0.003, respectively), stage 
IIc (p = 0.0004, p = 0.0005, p < 0.0001, respectively), or stage 
IIIa/b (p < 0.0001, all, respectively); stage I thymoma had in 
general a better OS than stage IIIa/b (p = 0.004, p = 0.02, 
p = 0.005, respectively); stage IIa/b had a slightly better OS 
than stage IIc (p = 0.02, p = 0.007, p = 0.01, respectively), and 
stage IIIa/b (p < 0.0001, p = 0.0003, p = 0.0001, respectively).
The prognostic significance of the modified Masaoka 
stage for OS and DFS continues after adjusting for any of the 
three histopathologic classifications and resection status (Table 4).
In comparing the predictive ability for each histopatho-
logic classification on OS and DFS, we evaluated the c-index 
TABLE 1.  Clinical Features of Patients with Thymoma (n = 413)
Clinical Characteristics
Sex: men, n (%) 205 (49.6)
Age at surgery in years, median (range) 56 (8–90)
Symptoms at presentation, n (%)a
  Myasthenia gravis 163 (40.4)
  Shortness of breath 52 (12.9)
  Chest pain 49 (12.2)
  Cough 48 (11.9)
  Weight loss 38 (9.4)
Resection status, n (%)a
  Complete resection 372 (92.3)
  Incomplete resection 9 (2.2)
  Biopsy only 22 (5.5)
Size of thymoma at resection in cm, median (range)b 6.8 (1.5–25.8)
Additional therapy, n (%)c
  Neoadjuvant radiation 5 (1.2)
  Adjuvant radiation 47 (11.7)
  Neoadjuvant chemotherapy 3 (0.7)
  Adjuvant chemotherapy 5 (1.2)
  Neoadjuvant chemoradiation 2 (0.5)
  Adjuvant chemoradiation 4 (1.0)
  Neoadjuvant and adjuvant radiation 4 (1.0)
  Neoadjuvant chemotherapy and adjuvant radiation 2 (0.5)
  No additional treatment 330 (82.1)
Follow-up, nd
  Recurrence and/or metastasis 52
  Death 190
  Death of disease 21
aSymptoms and resection status unknown for 10 patients (not included in denominator).
bSize of thymoma available in 355 cases.
cInformation on additional therapy available in 402 cases.
dFollow-up available in 376 patients.
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from each model. Univariately, modified Masaoka stage has 
the highest c-index for both OS and DFS (c = 0.66 for 
OS; c = 0.81 for DFS) followed by WHO (c = 0.62 for OS, 
c = 0.75 for DFS) and Bernatz (c = 0.59 for OS, too few cases 
for DFS). S&M has the lowest c-index (c = 0.54 for OS; c = 0.58 
for DFS).
Modified Masaoka stage strongly correlates with the 
proposed Moran stage (correlation coefficient, 0.95), suggesting 
similar prognostic strength.
Thymoma Size, Age, Weight Loss, and Resection 
Status Have Prognostic Significance in Thymomas
In univariate analysis, thymoma size, age, weight loss, 
and resection status are significantly associated with OS; 
thymoma size and weight loss are also associated with DFS 
(except for Bernatz classification in which weight loss is not 
significantly associated with DFS; Table 3).
If adjusted for any of the three histopathologic classifi-
cations or modified Masaoka stage, thymoma size continues to 
TABLE 2.  Outcome of Patients that Were Classified as the Same Subtype of Thymoma by All Three Reviewers
Morphologic Classification
Bernatz WHO Proposed Suster & Moran
Total number of cases 201 256 385
Sex: men, n (%) 100 (49.8) 123 (48.0) 185 (48.1)
Pathologists agree upon degree of invasion and  
follow-up available, n (%)
120 (59.7) 145 (56.6) 214 (55.6)
Median follow-up time, years (range) 7.5 (0–44) 7.7 (0–44) 7.5 (0–44)
Recurrence and/or metastasis, n 22 24 37
Death, n 69 82 113
Death of disease, n 9 10 14
5-year DFS estimate, % (95% CI) 89.5 (83.3–95.7) 90.3 (84.8–95.8) 89.8 (85.3–94.5)
5-year OS estimate, % (95% CI) 78.9 (71.2–86.6) 76.8 (69.7–84.0) 76.7 (70.7–82.6)
WHO, World Health Organization; DFS, disease-free survival; CI, confidence interval; OS, overall survival.
TABLE 3.  Results of Univariate Analysis of Thymomas for which All Reviewers Agreed upon WHO Classification, Bernatz 
Classification, or Proposed S&M Classification and Invasion and Follow-Up was Available
Overall Survival Disease-Free Survival
HR p Value HR p Value
WHO classification (n = 145)
  Age, median years (range) 54.0 (18–89) 1.02 0.003 0.99 0.45
  Thymoma size, median cm (range) 7.0 (1.5–25.8) 1.12 0.0004 1.17 0.001
  Weight loss, n (%) 11 (7.6) 2.22 0.02 3.72 0.01
  Resection statusa 0.44 0.04 0.26 0.052
  WHOb, n (%)
   A 20 (13.1) 1.0 0.001 1.0 0.0002
   AB 35 (23.4) 0.51 0.49
   B1 22 (14.5) 0.44 2.32
   B2 50 (33.8) 1.04 4.69
   B3 18 (12.4) 1.93 12.01
  Modified Masaoka stage, n (%)
   I 58 (40.0) 1.0 <0.0001 Nonestimable
   II 33 (22.8) 2.72
   III 44 (30.3) 2.16
   IV 10 (6.9) 8.39
   Continuous 1.65 <0.0001 4.37 <0.0001
  Proposed Moran stage, n (%)
   0 63 (43.4) 1.0 <0.0001 Nonestimable
   I 28 (19.3) 2.72
   IIa/b 34 (23.4) 1.64
   IIc 9 (6.2) 4.84
(Continued)
695Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 4, April 2015 Modified Masaoka Stage, Size, and Histopathologic Classifications
   IIIa/b 11 (7.6) 8.76
   Continuous 1.60 <0.0001 3.14 <0.0001
Bernatz classification (n = 120)
  Age, median years (range) 51.5 (17–82) 1.03 0.002 1.00 0.87
  Thymoma size, median cm (range) 6.5 (2.0–25.8) 1.16 0.0002 1.21 0.004
  Weight loss, n (%) 6 (5.0) 3.82 0.001 3.80 0.06
  Resection statusc 0.15 <0.0001 0.24 0.05
  Bernatz classification, n (%)
   Lymphocyte predominant 22 (18.3) 1.0 0.003 1.0 0.048
   Spindle cell predominant 26 (21.7) 2.19 0.64
   Mixed epithelial cell & lymphocyte 56 (46.7) 2.13 1.76
   Epithelial cell predominant 16 (13.3) 4.95 4.30
  Modified Masaoka stage, n (%)
   I 48 (40.0) 1.0 0.0005 Nonestimable
   II 24 (19.2) 2.18
   III 42 (35.8) 1.82
   IV 6 (5.0) 6.37
   Continuous 1.49 0.001 3.01 <0.0001
  Proposed Moran stage, n (%)
   0 50 (41.7) 1.0 <0.0001 Nonestimable
   I 21 (17.5) 2.35
   IIa/b 31 (25.8) 1.33
   IIc 11 (9.2) 4.18
   IIIa/b 7 (5.8) 7.39
   Continuous 1.47 0.0008 2.58 <0.0001
  Proposed Suster & Moran classification (n = 214)
   Age, median years (range) 54 (17–89) 1.03 <0.0001 1.00 0.96
   Thymoma size, median cm (range) 7 (1.5–25.8) 1.12 <0.0001 1.18 <0.0001
   Weight loss, n (%) 22 (10.3) 2.88 <0.0001 3.67 0.002
   Resection statusd 0.37 0.006 0.40 0.20
  Proposed Suster & Moran classification, n (%)
   Typical thymoma 196 (91.6) 1.0 0.0006 1.0 0.0001
   Atypical thymoma 18 (8.4) 2.63 4.50
  Modified Masaoka stage, n (%)
   I 85 (39.7) 1.0 <0.0001 Nonestimable
   II 45 (21.0) 2.14
   III 70 (32.7) 2.15
   IV 14 (6.5) 5.85
   Continuous 1.56 <0.0001 3.72 <0.0001
  Proposed Moran stage, n (%)
   0 91 (42.5) 1.0 <0.0001 Nonestimable
   I 39 (18.2) 2.30
   IIa/b 50 (23.4) 1.65
   IIc 19 (8.9) 3.77
   IIIa/b 15 (7.0) 6.17
   Continuous 1.52 <0.0001 2.81 <0.0001
Complete resection in a88.3% cases (5.5% incomplete, 6.2% biopsy only), c87.5% cases (5.8% incomplete, 6.7% biopsy only), d87.9% cases (4.2% incomplete, 7.9% biopsy only). 
Hazard ratio for complete vs. incomplete resection, among those with resection.
bMicronodular thymoma with lymphoid stroma (2.8%) were also identified (excluded from time-to-event analysis).
Statistical significant results are in bold.
WHO, World Health Organization; HR, hazard ratio.
TABLE 3.  (Continued)
Overall Survival Disease-Free Survival
HR p Value HR p Value
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be significantly associated with OS (Table 4). Thymoma size 
is significantly associated with DFS in WHO and proposed 
S&M classification after adjusting for modified Masaoka 
stage. Similar to what was found univariately, age remains 
significantly associated with OS (p ≤ 0.001). Weight loss is no 
longer significant for OS when adjusted for WHO, but contin-
ues to be significant for DFS (p = 0.03), as well as after adjust-
ing for Bernatz (OS only), proposed S&M (OS and DFS), and 
modified Masaoka staging (OS and DFS).
Year of Treatment Has No Impact on Survival
Because our patient population was recruited from 1948 
to 2008 we thought to investigate whether year of treatment 
has an effect on outcome given that treatment has changed over 
the years. We have compared OS and DFS for patients treated 
before 1988 versus 1988 to1998 versus after 1998 (given that 
radiation treatment has changed within the last 10–20 years 
with 2D planning before 1970s, 2D and 3D plans within the 
1980s and 1990s and intensity-modulated radiation therapy in 
the 2000s). We also compared OS and DFS from before 2007 
versus 2007 and later (given changes in the past years with 
more cases being done by thoracoscopy with lengths of hospi-
tal stay of 1–2 days versus 5–10 days previously). There is no 
difference in survival of these patient groups (OS: p = 0.46, 
p = 0.23, p = 0.83; DFS: p = 0.78, p = 0.13, p = 0.55; 1988–
1998 versus before 1988, after 1998 versus before 1998, and 
pre-2007 versus 2007 and later, respectively).
DISCUSSION
The significance of histopathologic classifications for 
outcome of thymomas is still debated and literature analysis 
shows conflicting results. Some evidence suggests that WHO 
and Bernatz classifications have prognostic value.10,15–17 For 
instance, studies have shown significant worse survival of B3 
thymoma versus types A-B2 thymoma,18 type A, and AB thy-
moma19 or type A, AB, and B1 thymoma.20 However, other 
studies did not find differences in survival between type B3 
thymoma or atypical thymoma and other thymomas21,22 and 
failed to show an association of WHO or proposed S&M clas-
sification with outcome.2,3,21 Furthermore, studies that identi-
fied prognostic value of the WHO or Bernatz classification 
usually included thymic carcinomas.
FIGURE 2.  Kaplan–Meier curves for overall survival for each morphologic classification and each staging system.
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Reproducibility might be, at least in part, responsible 
for conflicting outcome data of histopathologic classifica-
tions of thymomas. We recently reported an only moderate 
to substantial interobserver agreement for the current WHO 
classification, Bernatz classification, and proposed S&M clas-
sification (κ values: 0.65, 0.52, 0.74, respectively) in a study 
of 456 patients who underwent surgery for thymic epithelial 
neoplasm.9 In that study, three thoracic pathologists inde-
pendently reviewed all cases. We found that if adjusted for 
modified Masaoka staging, only Bernatz classification for one 
reviewer and all histopathologic classifications for another 
reviewer were significant for OS suggesting that reproducibil-
ity does affect the prognostic value of histopathologic classi-
fications of thymic epithelial neoplasms. Furthermore, Zucali 
et al.7 evaluated the effect of reproducibility of the WHO clas-
sification on outcome and found that an only moderate agree-
ment of the WHO classification affected the management in 
seven patients (of 129). Low power of study might also be 
a factor. For instance only one surgical pathologist reviewed 
52 cases in a study that did not show significant difference in 
TABLE 4.  Results of Multivariate Analysis of Thymomas for which All Reviewers Agreed upon WHO Classification, Bernatz 
Classification, or Proposed S&M Classification and Invasion and Follow-Up was Available
Overall Survival Disease-Free Survivala
Adjusted for HR p Value HR p Value
WHO classification (HR with reference = A)
  Age & sex AB: 0.51
B1: 0.44
B2: 1.04
B3: 1.93
<0.0001 AB: 0.60
B1: 3.30
B2: 6.86
B3: 18.34
0.0031
  Thymoma size AB: 0.37
B1: 0.30
B2: 0.85
B3: 1.31
0.008 AB: 0.21
B1: 0.86
B2: 3.53
B3: 7.73
0.006
  Modified Masaoka stage AB: 0.52
B1: 0.30
B2: 0.48
B3: 0.70
0.09 AB: 0.39
B1: 0.83
B2: 0.71
B3: 0.95
0.93
Bernatz classification (HR with reference = LP)
  Age & sex EP: 4.94
MEL: 1.82
Spindle: 1.27
0.002
  Thymoma size EP: 4.14
MEL: 1.92
Spindle: 2.56
0.06
  Modified Masaoka stage EP: 3.01
MEL: 1.69
Spindle: 2.82
0.04
Proposed Suster & Moran classification (HR for atypical thymoma vs. thymoma)
  Age & sex 3.42 <0.0001 4.65 0.0005
  Thymoma size 2.60 0.009 4.82 0.002
  Modified Masaoka stage 1.72 0.08 1.50 0.37
Modified Masaoka stage (HR for 1 full level increase in stage)
  WHO classification 1.72 0.001 3.95 0.0001
  WHO classification & thymoma size 1.30 0.17 5.14 0.0006
  Bernatz classification 1.47 0.02
  Bernatz classification & thymoma size 1.23 0.24
  Proposed Suster & Moran classification 1.49 <0.0001 3.53 <0.0001
  Proposed Suster & Moran classification & thymoma size 1.26 0.04 3.77 <0.0001
  Resection status 1.35 0.004 3.92 <0.0001
Thymoma size (HR for 1 cm increase)
  WHO classification 1.14 <0.0001 1.24 0.0003
  Bernatz classification 1.16 0.0002
  Proposed Suster & Moran classification 1.12 0.0001 1.19 <0.0001
  Modified Masaoka stage 1.11 0.0002 1.17 0.0006
aDisease-free survival models not performed for Bernatz.
Statistical significant results are in bold.
WHO, World Health Organization; HR, hzard ratio; LP, lymphocyte predominant; EP, epithelial cell predominant; MEL, mixed epithelial cell and lymphocyte; Spindle, spindle 
cell predominant.
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outcome between typical and atypical thymoma.21 In another 
study of 90 patients with thymic epithelial tumors that also did 
not show significant differences in survival between type A 
and B thymomas, two pathologists independently reviewed all 
cases; however, the authors did not state whether a consensus 
diagnosis was used.22
To avoid bias because of interobserver variability, we 
studied an “agreement cohort” which included only thymo-
mas in which three thoracic pathologists independently agreed 
upon a histopathologic subtype. Furthermore, cases that were 
diagnosed as thymic carcinoma by any reviewer were excluded 
because thymic carcinomas have consistently been shown to 
be a distinct group of tumors that have a worse outcome than 
thymomas.17,21,23,24 Our agreement rate of 62.0% for WHO 
classification of thymomas is higher than some of the previ-
ously reported rates, likely because our study includes only 
three reviewers and all reviewers have expertise in thoracic 
pathology and work together in one department. In contrast 
to our study, Zucali et al.7 reported a 49% agreement among 
four reviewers, at least one of which was a surgical patholo-
gist without a specific interest in thymic malignancies. In a 
study by Verghese et al.,8 17 pathologists with an interest in 
pulmonary pathology had a 9.5% near/total agreement (16–17 
identical diagnoses). Sakakura et al.25studied the concordance 
between an expert pathologist in thymic neoplasms and a gen-
eral pathologist and identified a rate of 63%, similar to our 
agreement rate. One study of the previous WHO classifica-
tion reported an agreement rate exceeding 90% between the 
first author and a consensus diagnosis attained by three senior 
pathologists.26 In that study, the first author received a histo-
pathologic review of the classification by a member of the 
WHO committee.
Using our approach, we show that all three histopatho-
logic classifications, WHO, Bernatz, and proposed S&M clas-
sification, are associated with OS and DFS. Moreover, we 
find that type B3 thymomas, epithelial predominant, or atypi-
cal thymomas have a worse outcome for the WHO, Bernatz, 
or proposed S&M classification, respectively, than other 
thymomas.
Outcome data for type A, AB, B1, and B2 thymomas 
or lymphocyte predominant, spindle cell predominant, and 
mixed epithelial and lymphocyte thymomas vary among stud-
ies and in general are not statistically different from each other. 
Similarly, we did not find a significant difference in outcome 
among types A, AB, B1, and B2 thymomas. Although several 
studies describe patients with type A thymomas have the best 
10-year survival,20,26,27 other studies, including ours, show 
patients with type AB and B1 thymomas have a better OS.10 
Furthermore, we did not distinguish between type A and type 
A thymomas with cytologic atypia because the latter was only 
recently described, after the review of our cases.28 Moreover, 
only a few such cases have been reported, all of which had an 
excellent prognosis.
Although all three histopathologic classifications are 
associated with outcome in our study, only Bernatz classifica-
tion independently predicts OS after adjusting for modified 
Masaoka stage. This might be because of four histopathologic 
categories in the Bernatz classification in contrast to five cat-
egories of the WHO classification. Furthermore, the number 
of cases for the Bernatz classification is lower than for WHO 
and proposed S&M classification which might lead to pos-
sible selection bias. Conceivably, this might also be a chance 
finding only, given that the result was not a very significant 
result with a p value of 0.04. Moreover, the low number of cat-
egories in the proposed S&M classification (typical and atypi-
cal thymoma) might not provide enough variability to achieve 
a statistically significant result.
Our study confirms that both modified Masaoka stag-
ing1–3 and proposed Moran staging6 are independent prognos-
tic parameters. Kim et al.18 previously showed that modified 
Masaoka staging was the most significant risk factor with 
respect to tumor-related survival. Histopathologic assessment 
of invasion of thymomas is crucial for modified Masaoka 
staging, as it would be for the proposed Moran staging, spe-
cifically for the distinction between stage I and II (modified 
Masaoka stage) or 0 and I (proposed Moran stage) thymo-
mas which requires histologic distinction between encapsu-
lated and minimally invasive thymoma. To exclude possible 
bias because of interobserver variability of invasion, we solely 
included thymomas for which all reviewers agreed on extent 
of invasion. In all three histopathologic classifications, WHO, 
Bernatz, and proposed S&M classification, modified Masaoka 
stage I thymomas have the best OS and DFS and stage IV 
the worst. Furthermore, we show that stage I thymomas have 
a significant better OS than stage II thymoma for WHO and 
proposed S&M classification and show a trend for Bernatz 
classification. These results support that invasion through the 
tumor capsule is an important histopathologic parameter. Our 
results are in contrast to some previous studies that failed to 
show differences in survival between Masaoka stage I and II 
patients.5,29,30 The discrepancy between our results and previ-
ous studies might be the problematic reproducibility of inva-
sion through the tumor capsule. Indeed we observed that most 
disagreements for invasion occurred between encapsulated 
and minimally invasive thymomas.9
Moran et al.6 proposed a new staging system for thy-
momas with the goal to better stratify patients who may need 
additional therapy. In that particular staging system, only 
invasive tumors were assigned a staging number, whereas 
encapsulated tumors (stage 0) were considered equivalent to 
in situ carcinomas elsewhere. Furthermore, the authors pro-
posed that this staging system could be easily translated into 
clinical practice not only by pathologists but also oncologists, 
surgeons, and interventional radiation oncologists. Moran 
et al. showed that patients with stages II and III had a worse 
outcome than patients with stages 0 and I but no significant 
differences were identified in survival between stage 0 and I 
thymomas.
We identified a strong correlation between modified 
Masaoka and proposed Moran staging. This finding sug-
gests that the proposed Moran staging has similar prognostic 
strength as the modified Masaoka staging.
To compare the predictive ability of the modified 
Masaoka staging and each histopathologic classification for 
outcome, we analyzed the c-index for each model. Our results 
show that modified Masaoka staging is the best predictor of 
OS followed by WHO and then Bernatz classification (too few 
cases were available for DFS). Interestingly, even though the 
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proposed S&M classification appears to be the easiest clas-
sification with only two subtypes, this classification has the 
lowest ability to predict outcome. Our results suggest that 
modified Masaoka staging is the most powerful system to pre-
dict outcome for thymomas and histopathologic classifications 
might not be as useful for predicting prognosis. However, if a 
histopathologic classification is to be used to predict progno-
sis, our data suggest that the WHO classification would be the 
most useful.
Recently, the International Association for the Study 
of Lung Cancer (IASLC) and the International Thymic 
Malignancy Interest Group (ITMIG) proposed a tumor (T), 
nodal (N), metastases (M) staging system for the forthcom-
ing (8th) edition of the American Joint Committee of Cancer 
and Union for International Cancer Control.31 We recently 
have shown that the reproducibility for the proposed IASLC/
ITMIG staging is almost perfect (κ = 0.92)9; therefore, it 
seems likely that reproducibility does not affect this staging. 
Moreover, the proposed IASLC/ITMIG staging does not dis-
tinguish between encapsulated and minimally invasive thy-
momas which had the highest interobserver variability in our 
previous study.9 However, studies are needed to determine 
whether the proposed IASLC/ITMIG staging is prognostically 
superior to the modified Masaoka staging.
We identified that pathologic and clinical parameters 
such as thymoma size, age, weight loss, and resection sta-
tus have prognostic value. Wright et al.,32 Bae et al.,33 and 
Safieddine et al.34 have previously shown that thymic tumor 
size is an independent predictor of recurrence; Wright et al. 
and Bae et al. used a cutoff of 8 cm; smaller tumors had fewer 
recurrences. Similarly, Harnath et al.2 showed that thymic epi-
thelial tumors of less than 8.5 cm have an independent favor-
able prognosis. Nakagawa et al.15 also identified thymoma size 
as a prognostic parameter for OS independent of the WHO 
classification if a cutoff of 10 cm was used. Demirci et al.4 
showed that thymic tumors less than or equal to 6 cm in size 
had a longer 5-year OS and local recurrence-free survival; 
however, this significance was lost in multivariate analysis. 
Ruffini et al.30 analyzed 2030 patients from the European 
Society of Thoracic Surgeons (ESTS) database and showed 
that thymic tumor size was associated with OS in univariate 
analysis but again this significance was lost in multivariate 
analysis. Except for the studies by Nakagawa et al. and Bae et 
al., all studies also included thymic carcinomas. Our study of 
thymomas confirms that size is a prognostic factor indepen-
dent of WHO classification, and moreover, we show that size 
is independent of Bernatz and proposed S&M classifications 
and modified Masaoka staging or proposed Moran staging. 
Therefore, thymoma size as measured at time of gross exami-
nation of the specimen is important to report and should be 
considered in a staging scheme.
We also identify age as an independent prognostic 
parameter for outcome, with older patients having worse 
outcome than younger. However, an analysis of the subset 
of patients who died because of disease would be important. 
Because of the low number of patients who died because of 
disease, statistical analysis for that patient population could 
not be performed in our study. Our results confirm a study by 
Filosso et al.5 that showed that age is an independent prog-
nostic parameter in thymomas. Aydiner et al.35 also showed 
that patients above 50 years of age had a significant lower 
survival than younger patients; however that was not con-
firmed in multivariate analysis. The analysis of the ESTS 
database30 also revealed age as an independent prognostic 
parameter for thymic tumors but the database included also 
thymic carcinomas.
We confirm resection status as an important prognostic 
parameter. Demirci et al.4 showed that resection status is an 
independent predictor of 5-year OS with R0 resections having 
the best survival followed by R1, R2 resections and biopsies 
having the worst survival. Similarly, using the ESTS data-
base,30 R0 resected tumors had a significant better OS than 
any other thymic epithelial tumors and resection status was 
found to be an independent prognostic factor. Interestingly, 
the analysis of the ESTS database also evaluated the signifi-
cance of resection status by histology; resection status was 
only significant for OS for a group that contained B2 and 
B3 thymomas, not for A-AB-B1 thymomas or thymic car-
cinomas. Harnath et al.2 also showed that resection status of 
thymic epithelial tumors has significance for OS and DFS 
but like in our study, resection status was not an indepen-
dent prognostic parameter. All these studies included thymic 
carcinomas. In a study of thymomas, Filosso et al.5 dem-
onstrated that resection status is an independent prognostic 
factor. In contrast to Filosso et al., in our study, resection 
status is not independent of the modified Masaoka staging. 
This might be because of the low number of incompletely 
resected or biopsied thymomas in our study. In contrast to 
our study, Filosso et al. had 537 patients included; in 88% of 
these patients, complete resection was achieved, 8% had an 
incomplete resection, in 4% information regarding resection 
status was missing.
Although treatment of thymoma is not widely standard-
ized, over the years treatment has changed. For instance, radia-
tion treatment has changed from 2D planning before 1970s, 2D 
and 3D plans within the 1980s and 1990s and then intensity-
modulated radiation therapy in the 2000s. Surgical resection 
of thymoma used to be done solely by thoracotomy; however, 
within the last 6–8 years more cases were being done by tho-
racoscopy which results in a much shorter hospital stay of 1–2 
days versus 5–10 days previously. However, we find no dif-
ference in survival of patient groups within different decades. 
Similarly, in the analysis of the ESTS database30 years of inter-
vention (categorized as 1990–1995, 1996–2002, 2002–2007, 
2008–2011) were not associated with OS although a higher 
risk of recurrence for patients who were treated within the 
more recent years was identified.
In conclusion, histopathologic classifications includ-
ing the current WHO, Bernatz, and proposed S&M classi-
fication have prognostic value for thymoma although they 
are not independent of modified Masaoka stage. Modified 
Masaoka stage and proposed Moran stage correlate strongly 
and are independent prognostic parameters for thymoma. 
Thymoma size is another pathologic independent prognos-
tic parameter in thymoma. Year of treatment has no impact 
on survival.
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